Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers

Based on the results of the pivotal CLARITY study, cladribine tablets were approved for use in the European Union in 2017 as a high-efficacy therapy for highly active relapsing-remitting multiple sclerosis (MS). Cladribine tablets are used as an induction therapy: half of the total dose is given in...

Descripción completa

Detalles Bibliográficos
Autores principales: Habek, Mario, Drulovic, Jelena, Brecl Jakob, Gregor, Barbov, Ivan, Radulovic, Ljiljana, Rajda, Cecilia, Rejdak, Konrad, Turčáni, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Guidelines
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672547/
https://www.ncbi.nlm.nih.gov/pubmed/36394714
http://dx.doi.org/10.1007/s40120-022-00422-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672547/
https://www.ncbi.nlm.nih.gov/pubmed/36394714
http://dx.doi.org/10.1007/s40120-022-00422-z

Ejemplares similares